Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 300 |
| Active Pipeline (Recruiting Now) | 122 (49) |
| Completed vs Stopped Early | 123 / 55 (18.3%) |
| Median Closed Actual Enrollment | 192 participants |
| Physical Hospital Site Disclosure | 99.4% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 131 (21 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hosp. Univ. 12 de Octubre | Madrid | 85 |
| National Taiwan University Hospital | Taipei | 75 |
| Hosp. Univ. Vall D Hebron | Barcelona | 74 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06500884 | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | Phase II | RECRUITING |
| NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Phase III | RECRUITING |
| NCT05179876 | A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | Phase III | RECRUITING |
| NCT07258511 | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refract | Phase III | RECRUITING |
| NCT07586202 | A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Johnson & Johnson / Janssen Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.